Recruiting
ALBUMINUS: Dose reduction of human albumin during large-volume paracentesis in patients with cirrhosis
2026-526167-38-00· Phase 4· Amsterdam UMC Stichting· Source
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Recruiting
HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of venetoclax upon recurrence of the disease after previous treatment
2025-524283-38-00· Phase 3· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117· Phase 3· AstraZeneca· Source
Recruiting
ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
NCT06716021· Phase 3· Milestone Pharmaceuticals Inc.· Source
Not yet recruiting
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
NCT07486687· Phase 3· The Netherlands Cancer Institute· Source
Active, not recruiting
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NCT07219602· Phase 3· NewAmsterdam Pharma· Source
Recruiting
T3-4-Hypo trial
2024-513883-24-00· Phase 3· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00· Phase 3· Amgen Inc.· Source
Recruiting
ASPIRING
2024-516188-10-00· Phase 4· University Of Edinburgh· Source
Recruiting
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
NCT07048262· Phase 2· CSL Behring· Source
Recruiting
Continuing ovulation induction with letrozole versus switching to gonadotropins in women with polycystic ovary syndrome (MOVIN-II study)
2024-519354-36-00· Phase 4· Amsterdam UMC Stichting· Source
Active, not recruiting
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347· Phase 3· Sanofi· Source
Recruiting
Tocilizumab Dose Optimization in Rheumatoid Arthritis
2025-520513-30-00· Phase 4· Reade revalidatie & reumatologie centrum te Amsterdam· Source
Recruiting
A multi-centred, partially randomised, patient-preference trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer.
NCT02371304· Phase 3· Amsterdam UMC Stichting· Source
Recruiting
Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis
NCT06766461· Phase 4· Erasmus Medical Center· Source
Recruiting
The Effect of ColcHicine on the Incidence of Knee or Hip Replacements
NCT06578182· Phase 3· Sint Maartenskliniek· Source
Recruiting
Colchicine and Inflammation in Aortic Stenosis (CHIANTI) trial
2024-513486-39-00· Phase 3· Stichting Radboud universitair medisch centrum· Source
Recruiting
Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial
2024-513092-40-00· Phase 4· Stichting Radboud universitair medisch centrum· Source
Active, not recruiting
Prevention of the return of nephrotic syndrom in children by adding levamisole to prednisolone treatment
2024-517467-23-00· Phase 3· Amsterdam UMC Stichting· Source
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647· Phase 3· AstraZeneca· Source
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738· Phase 3· AstraZeneca· Source
Active, not recruiting
Dose tapering and Early Discontinuation to InCreAse cosT-effictIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1 (NVALT-30 - Dedication-1)
NCT04909684· Phase 3· Stichting Radboud universitair medisch centrum· Source
Active, not recruiting
DUTCH Weight Control in Atrial Fibrillation Study
NCT06184633· Phase 4· Rijnstate Hospital· Source
Recruiting
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
NCT06275958· Phase 3· Leiden University Medical Center· Source
Recruiting
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
NCT06187441· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Recruiting
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
NCT05791409· Phase 1/2· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Active, not recruiting
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873· Phase 3· AstraZeneca· Source
Recruiting
Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume castration-sensitive prostate cancer: a randomized Nationwide Study
2023-506698-36-00· Phase 3· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source
Active, not recruiting
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821· Phase 3· BeOne Medicines· Source
Active, not recruiting
Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS
2022-502664-21-00· Phase 4· Amsterdam UMC· Source
Active, not recruiting
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976· Phase 3· Genmab· Source
Active, not recruiting
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
NCT05374291· Phase 3· University Medical Center Groningen· Source
Active, not recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797· Phase 3· European Myeloma Network B.V.· Source
Active, not recruiting
LEGACY
NCT05125276· Phase 4· Amsterdam UMC· Source
Active, not recruiting
Personalized dosing of ocrelizumab in MS
2024-513193-22-00· Phase 4· Amsterdam UMC Stichting· Source
Active, not recruiting
Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiation in
sarcopenic head and neck cancer patients
2024-514919-10-00· Phase 4· Universitair Medisch Centrum Utrecht· Source
Not yet recruiting
Avelumab Short Maintenance Trial
2024-512975-11-01· Phase 4· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source
Active, not recruiting
Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone
NCT04392037· Phase 2· Amsterdam UMC, location VUmc· Source
Active, not recruiting
Blood-borne Assessment of Stromal activation in esophageAL adenocarcinoma to guide tocilizumab Therapy: a randomized phase II proof-of-concept study (BASALT)
2023-509458-77-00· Phase 2· Amsterdam UMC· Source
Recruiting
Induction Chemotherapy for Locally Recurrent Rectal Cancer
NCT04389086· Phase 3· Catharina Ziekenhuis Eindhoven· Source
Active, not recruiting
Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)
NCT04483739· Phase 3· European Myeloma Network B.V.· Source
Active, not recruiting
A Randomized Controlled Phase II Clinical Trial with Intradermal IMO-2125 (Tilsotolimod) in pT3-4 cN0M0 Melanoma (Intrim 1 study)
2023-509461-20-00· Phase 2· Amsterdam UMC· Source
Recruiting
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
NCT03968393· Phase 4· Population Health Research Institute· Source
Recruiting
Evaluating, clinical and immunological effects of rituximab with cyclophosphamide compared to rituximab alone in AAV patients
2023-507868-39-00· Phase 4· Academisch Ziekenhuis Leiden· Source
Active, not recruiting
Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer
NCT03540420· Phase 2· Norwegian University of Science and Technology· Source
Active, not recruiting
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
NCT03574571· Phase 3· Memorial Sloan Kettering Cancer Center· Source
Active, not recruiting
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022· Phase 2· Astellas Pharma Global Development, Inc.· Source
Recruiting
DRUP trial
NCT02925234· Phase 2· Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting· Source
Active, not recruiting
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
NCT01946204· Phase 3· Aragon Pharmaceuticals, Inc.· Source
Showing 50 of 51.